JP2016501520A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501520A5
JP2016501520A5 JP2015543449A JP2015543449A JP2016501520A5 JP 2016501520 A5 JP2016501520 A5 JP 2016501520A5 JP 2015543449 A JP2015543449 A JP 2015543449A JP 2015543449 A JP2015543449 A JP 2015543449A JP 2016501520 A5 JP2016501520 A5 JP 2016501520A5
Authority
JP
Japan
Prior art keywords
substituted
alkynyl
alkenyl
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015543449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501520A (ja
JP6463687B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/074552 external-priority patent/WO2014080004A1/en
Publication of JP2016501520A publication Critical patent/JP2016501520A/ja
Publication of JP2016501520A5 publication Critical patent/JP2016501520A5/ja
Application granted granted Critical
Publication of JP6463687B2 publication Critical patent/JP6463687B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015543449A 2012-11-26 2013-11-25 Fgfr3の発現の調節のための組成物及び方法 Expired - Fee Related JP6463687B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261729922P 2012-11-26 2012-11-26
US61/729,922 2012-11-26
PCT/EP2013/074552 WO2014080004A1 (en) 2012-11-26 2013-11-25 Compositions and methods for modulation of fgfr3 expression

Publications (3)

Publication Number Publication Date
JP2016501520A JP2016501520A (ja) 2016-01-21
JP2016501520A5 true JP2016501520A5 (cg-RX-API-DMAC7.html) 2016-12-01
JP6463687B2 JP6463687B2 (ja) 2019-02-06

Family

ID=49639882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015543449A Expired - Fee Related JP6463687B2 (ja) 2012-11-26 2013-11-25 Fgfr3の発現の調節のための組成物及び方法

Country Status (11)

Country Link
US (1) US9725723B2 (cg-RX-API-DMAC7.html)
EP (1) EP2922955B1 (cg-RX-API-DMAC7.html)
JP (1) JP6463687B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150088305A (cg-RX-API-DMAC7.html)
CN (1) CN104903448B (cg-RX-API-DMAC7.html)
BR (1) BR112015012051A2 (cg-RX-API-DMAC7.html)
CA (1) CA2889993A1 (cg-RX-API-DMAC7.html)
DK (1) DK2922955T3 (cg-RX-API-DMAC7.html)
MX (1) MX2015006289A (cg-RX-API-DMAC7.html)
RU (1) RU2015120645A (cg-RX-API-DMAC7.html)
WO (1) WO2014080004A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009323766B2 (en) 2008-12-02 2016-10-06 Wave Life Sciences Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
SG177564A1 (en) 2009-07-06 2012-02-28 Ontorii Inc Novel nucleic acid prodrugs and methods of use thereof
EP2620428B1 (en) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
WO2012068405A2 (en) 2010-11-17 2012-05-24 Isis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
SG10201912895PA (en) 2012-07-13 2020-02-27 Wave Life Sciences Ltd Chiral control
JP6268157B2 (ja) 2012-07-13 2018-01-24 株式会社Wave Life Sciences Japan 不斉補助基
BR112015012051A2 (pt) 2012-11-26 2017-12-12 Roche Innovation Ct Copenhagen As composições e métodos para modulação de expressão de fgfr3
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
PT3094728T (pt) 2014-01-16 2022-05-19 Wave Life Sciences Ltd Desenho quiral
JP7085985B2 (ja) 2016-03-04 2022-06-17 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR102473372B1 (ko) 2018-03-19 2022-12-05 다이호야쿠힌고교 가부시키가이샤 알킬황산나트륨을 포함하는 의약 조성물
WO2021153703A1 (ja) * 2020-01-31 2021-08-05 国立大学法人京都大学 軟骨形成異常症の治療
WO2022211095A1 (ja) * 2021-03-31 2022-10-06 ルクサナバイオテク株式会社 Fgfr3のアンチセンスオリゴヌクレオチド

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699808A (en) 1944-10-06 1955-01-18 Mark W Lowe Apparatus for peeling tomatoes
US2699508A (en) 1951-12-21 1955-01-11 Selectronics Inc Method of mounting and construction of mounting for low frequency piezoelectric crystals
US4914210A (en) 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
US4962029A (en) 1987-10-02 1990-10-09 Cetus Corporation Covalent oligonucleotide-horseradish peroxidase conjugate
JPH08504559A (ja) 1992-12-14 1996-05-14 ハネウエル・インコーポレーテッド 個別に制御される冗長巻線を有するモータシステム
US5656408A (en) 1996-04-29 1997-08-12 Xerox Corporation Coated carrier particles
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
JP4236812B2 (ja) 1997-09-12 2009-03-11 エクシコン エ/エス オリゴヌクレオチド類似体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20030087854A1 (en) * 2001-09-10 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of fibroblast growth factor receptor 3 expression
CN102180924A (zh) 1999-05-04 2011-09-14 桑塔里斯制药公司 L-核糖-lna类似物
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
EP1562971B1 (en) 2002-11-05 2014-02-12 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
ATE442152T1 (de) 2002-11-18 2009-09-15 Santaris Pharma As Antisense-entwurf
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
US7427672B2 (en) 2003-08-28 2008-09-23 Takeshi Imanishi Artificial nucleic acids of n-o bond crosslinkage type
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumor agent against multiple myeloma
CN102908630B (zh) 2006-01-27 2014-11-19 Isis制药公司 6-修饰的双环核酸类似物
EP2015758B1 (en) 2006-05-05 2014-04-02 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression apob
EP2066684B1 (en) 2006-05-11 2012-07-18 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
CA2662978A1 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
MX2009002856A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Conjugados polimericos que contienen porciones cargadas positivamente.
EP2090127A2 (en) 2006-10-30 2009-08-19 Nokia Corporation Method, apparatus and system providing operator controlled mobility for user equipment
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
ES2388590T3 (es) 2007-05-30 2012-10-16 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos con puente aminometileno N-sustituido.
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2009006478A2 (en) 2007-07-05 2009-01-08 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009090182A1 (en) 2008-01-14 2009-07-23 Santaris Pharma A/S C4'-substituted - dna nucleotide gapmer oligonucleotides
AT507215B1 (de) 2009-01-14 2010-03-15 Boehler Edelstahl Gmbh & Co Kg Verschleissbeständiger werkstoff
PE20120553A1 (es) * 2009-03-25 2012-05-18 Genentech Inc Anticuerpos anti-fgfr3
WO2011139842A2 (en) * 2010-04-28 2011-11-10 Marina Biotech, Inc. Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
US9984408B1 (en) 2012-05-30 2018-05-29 Amazon Technologies, Inc. Method, medium, and system for live video cooperative shopping
BR112015012051A2 (pt) 2012-11-26 2017-12-12 Roche Innovation Ct Copenhagen As composições e métodos para modulação de expressão de fgfr3
US9778708B1 (en) 2016-07-18 2017-10-03 Lenovo Enterprise Solutions (Singapore) Pte. Ltd. Dual sided latching retainer for computer modules

Similar Documents

Publication Publication Date Title
JP2016501520A5 (cg-RX-API-DMAC7.html)
JP2016503300A5 (cg-RX-API-DMAC7.html)
JP2013508347A5 (cg-RX-API-DMAC7.html)
JP2013505929A5 (cg-RX-API-DMAC7.html)
JP2015042636A5 (ja) 有機化合物
JP2017119663A5 (cg-RX-API-DMAC7.html)
JP2015181191A5 (cg-RX-API-DMAC7.html)
JP2009535462A5 (cg-RX-API-DMAC7.html)
JP2013102146A5 (ja) 化合物
JP2010095546A5 (cg-RX-API-DMAC7.html)
JP2013521295A5 (cg-RX-API-DMAC7.html)
JP2014509612A5 (cg-RX-API-DMAC7.html)
JP2010254680A5 (ja) 複素環化合物、及び発光素子
JP2014526533A5 (cg-RX-API-DMAC7.html)
JP2012528196A5 (cg-RX-API-DMAC7.html)
JP2010254679A5 (ja) トリアゾール誘導体、発光素子、及び発光装置
JP2011016798A5 (cg-RX-API-DMAC7.html)
JP2014508179A5 (cg-RX-API-DMAC7.html)
JP2018531301A5 (cg-RX-API-DMAC7.html)
JP2011079866A5 (cg-RX-API-DMAC7.html)
JP2014101364A5 (cg-RX-API-DMAC7.html)
JP2019507133A5 (cg-RX-API-DMAC7.html)
JP2015044793A5 (ja) 有機化合物
JP2011079832A5 (cg-RX-API-DMAC7.html)
JP2015044795A5 (ja) トリフルオロフェニル誘導体